Kidney Cancer and 2014: Is Innovation Really Over?

ABSTRACT

2014 has been a year of significant innovations on kidney cancer treatments, the most relevant of which will be shown below. In particular, we analyzed the consolidated knowledge regarding the role of surgery in localized and advanced renal cell carcinoma and the targeted therapies already approved for metastatic renal cell carcinoma. Furthermore, we examined the outstanding issues, with particular reference to the choice of the second-line and the role of adjuvant and neoadjuvant treatments. Finally, we outlined the future therapeutic perspectives and those definitely abandoned.

KEYWORDS:

• metastatic renal cell carcinoma
• targeted agents

Financial & competing interests disclosure

F Massari has consultancies for Pfizer, Novartis, speaker’s fee from Pfizer, GSK, Novartis, Janssen, Sanofi-Aventis, Pierre Fabre; G Tortora has consultancy role for Novartis, Pfizer and GSK. The work was supported by Associazione Italiana Ricerca sul Cancro (AIRC-IG 11930, AIRC 5 per mille 12214). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.